Nobilis Therapeutics leadership will be attending J.P.Morgan’s 36th Annual Healthcare Conference that will take place in San Francisco on January 8-11. If you are interested in setting up a f2f meeting with our team, please send us an email.
News
- Nobilis Therapeutics Enters into Collaboration with The Linde Group to Support Its Clinical Research Program to Study a drug/device combination for Treatment of PTSD and Other CNS Disorders. January 10, 2019
- Nobilis Therapeutics Announces IND Filing for a Phase IIb Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Posttraumatic Stress Disorder January 6, 2019
- Nobilis Collaborates on a Study of Argon Use to Treat Diabetic Wounds, Publishes Positive Results January 2, 2019
- Meet us at JP Morgan Healthcare Conference on Jan 7-10 in San Francisco. We have a lot of exciting updates! December 20, 2018
- Nobilis Therapeutics just published an article “Xenon as Promising Treatment for Patients with PTSD: Case Report, Justification of Approach and Review of Literature” in Annals of Psychiatry and Mental Health. November 28, 2018
Recent Posts
- Nobilis Therapeutics Enters into Collaboration with The Linde Group to Support Its Clinical Research Program to Study a drug/device combination for Treatment of PTSD and Other CNS Disorders.
- Nobilis Therapeutics Announces IND Filing for a Phase IIb Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Posttraumatic Stress Disorder
- Nobilis Collaborates on a Study of Argon Use to Treat Diabetic Wounds, Publishes Positive Results
- Meet us at JP Morgan Healthcare Conference on Jan 7-10 in San Francisco. We have a lot of exciting updates!
- Nobilis Therapeutics just published an article “Xenon as Promising Treatment for Patients with PTSD: Case Report, Justification of Approach and Review of Literature” in Annals of Psychiatry and Mental Health.
Recent Comments